Loading
Diabetes Care / Artificial Intelligence · Journal article
Journal of Diabetes and Metabolic Disorders · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This structured narrative review of six peer-reviewed empirical studies and three preprints suggests that clinician-facing AI tools may support guideline-concordant care when applied to clearly defined, bounded decision tasks integrated into clinical workflow. However, the overall evidence base is small, heterogeneous, and largely indirect for diabetes care, with most studies not evaluating patient outcomes. The authors conclude that prospective cardiometabolic studies are needed to establish effectiveness, safety, usability, and patient outcomes.
Structured narrative review. Studies of clinician-facing AI tools in clinical decision-making that evaluated guideline adherence, concordance outcomes, or physician-versus-AI recommendations.. Intervention: Clinician-facing artificial intelligence tools (types included: EHR-integrated pathways, NLP-based adherence measurement, decision-tree clinical decision support systems). Compared with: Physician recommendations or clinical decision-making without AI support.
Six peer-reviewed empirical studies met core eligibility criteria, including one real-world EHR-integrated pathway study, one NLP-based adherence measurement study, one randomized simulation trial, and three AI-versus-physician comparative studies Findings were most favorable for bounded tasks embedded in workflow or structured scenarios Evidence was weaker for complex real-world decisions
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that current evidence for AI-driven guideline adherence support is limited and heterogeneous. AI tools may be useful for clearly defined, bounded tasks integrated into workflow, but effectiveness for complex real-world decisions and effects on patient outcomes remain largely unevaluated.
A structured narrative review of six heterogeneous peer-reviewed studies plus three preprints, showing early promise for bounded AI tasks but acknowledging small, indirect evidence base without patient outcome data in most studies.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that current evidence for AI-driven guideline adherence support is limited and heterogeneous. AI tools may be useful for clearly defined, bounded tasks integrated into workflow, but effectiveness for complex real-world decisions and effects on patient outcomes remain largely unevaluated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Purpose. To synthesize empirical evidence on whether clinician-facing artificial intelligence (AI) tools improve clinical practice guideline adherence and whether AI-generated recommendations are concordant with physician decision-making.Methods. We conducted a structured narrative review aligned with SANRA and informed by narrative synthesis guidance. PubMed/MEDLINE, Embase, Scopus, Web of Science, and Google Scholar were searched for studies published from January 2020 to May 2026; earlier directly relevant studies were identified through citation tracking. Eligible studies evaluated clinician-facing AI tools, guideline adherence or concordance outcomes, or physician-versus-AI recommendations. Preprints were considered separately as emerging evidence and were not included in the peer-reviewed core synthesis.Results. Six peer-reviewed empirical studies met the core eligibility criteria. They included one real-world EHR-integrated pathway study, one NLP-based adherence measurement study, one randomized simulation trial of a decision-tree CDSS, and three AI-versus-physician comparative studies. Findings were most favorable for bounded tasks embedded in workflow or structured scenarios. Evidence was weaker for complex real-world decisions, and several studies did not evaluate patient outcomes. Three 2026 preprints were summarized separately as preliminary evidence.Conclusion. Early evidence suggests that clinician-facing AI may support guideline-concordant care when applied to clearly defined decision tasks and integrated into clinical workflow. However, the evidence base remains small, heterogeneous, and largely indirect for diabetes care. Prospective cardiometabolic studies are needed to evaluate effectiveness, safety, usability, and patient outcomes.Supplementary information. The online version contains supplementary material available at 10.1007/s40200-026-02030-2.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.